Regenerative biotechnology
Gencell® Neuromodulatory CTM
Mesenchymal stem cells pretreated with fluoxetine for immunomodulation and targeted tissue regeneration.
Injectable solution of mesenchymal stem cells pretreated with fluoxetine, designed to enhance cellular viability, induce neuronal differentiation, and optimize immune response in systemic regenerative processes.
Composition
Mesenchymal stem cells pretreated with fluoxetine at different cellular concentrations.
Pharmaceutical form
Injectable solution for controlled intravenous administration.
Presentation
Monovette with 4 ml.
Therapeutic Properties
Mesenchymal stem cells modulate inflammation, promote cellular proliferation, and adapt to specific lineages. Pretreatment with fluoxetine enhances their viability, neuronal differentiation, and tissue regenerative capacity.
- Systemic inflammation modulation.
- Stimulation of regulatory lymphocytes.
- Prevention of cellular apoptosis.
- Promotion of tissue regeneration.
- Induction of neuronal differentiation.
- Improvement of cellular viability.
- Activation of the MAPK pathway.
- Regulation of gene expression.
Mechanism of action & Clinical data
Mesenchymal stem cells adhere to injured endothelium and migrate to the affected site. They secrete anti-inflammatory factors, regulate pro-inflammatory cytokines, and, after pretreatment with fluoxetine, activate MAPK pathways promoting cellular differentiation, survival, and adaptation to the tissue environment.